Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.74
−$0.01 · -0.57%
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
Latest quote
$1.74
−$0.01 · -0.57%
After-hours
$1.77
+$0.03 · +1.72%
Sep 14, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
Day range
Current $1.74
52-week range
Current $1.74
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
28
Expensive
Sentiment
45
Mixed
Risk
63
High Risk
Momentum
32
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
Day range
Current $1.74
52-week range
Current $1.74
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | 55.18K USD | 140.11K USD | 164.99K USD |
| Gross profit | — | — | 55.18K USD | 140.11K USD | 164.99K USD |
| Research and development | 10.21M USD | 10.79M USD | 11.52M USD | 8.38M USD | 7.16M USD |
| Selling, general, and administrative | 8.5M USD | 9.56M USD | 10.79M USD | 9.54M USD | 6.83M USD |
| Operating expenses | 18.71M USD | 20.35M USD | 22.31M USD | 17.92M USD | 13.99M USD |
| Interest income | 244.39K USD | 357.1K USD | 494.23K USD | 375.36K USD | 12.5K USD |
| Depreciation and amortization | 94.05K USD | 84.07K USD | 83.58K USD | 64.17K USD | 15.48K USD |
| Operating income | −18.71M USD | −20.35M USD | −22.25M USD | −17.78M USD | −13.83M USD |
| Net income | −20.16M USD | −20.41M USD | −22.27M USD | −17.59M USD | −13.89M USD |
Company facts updated Sep 15, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$7.80
348.28% upsideFunds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
